Santen Pharmaceutical and Arctic Vision have signed a commercial collaboration agreement for the ARVN001to treat uveitic ...

Vidac will use the new funds to initiate a Phase IIb trial of its lead candidate VDA-1102 in patients with actinic keratosis.

Lord Vallance stated the government sees investment, innovation, and public-private partnership as crucial to UK healthcare.

With the boom in eClinical solutions showing no signs of slowing, adding a “human at the center” perspective can help ...

In the global pharmaceutical industry, there were two private equity deals announced in Q3 2024, worth a total value of $7.5m, according to GlobalData's Deals Database.

In the global pharmaceutical industry, there were three private equity deals announced in Q3 2024, worth a total value of $4.2m, according to GlobalData's Deals Database.

In the global pharmaceutical industry, there were eight M&A deals announced in Q3 2024, worth a total value of $1.3bn, according to GlobalData's Deals Database.

In Canada pharmaceutical industry, there were two private equity deals announced in Q3 2024, worth a total value of $4.2m, according to GlobalData's Deals Database.

The company reported that it does not have sufficient cash reserves to operate for the next 12 months, can only fund operations into Q1 2025.

The EMA has granted approval for Sanofi/Regeneron’s Dupixent (dupilumab) to treat EoE in children as young as one.

In the globally important pharmaceutical industry, it is fair to say that competition is fierce, and the landscape is ever-evolving. This makes the role of robust marketing and sales intelligence even ...